Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Calcitriol is administered orally or by IV injection, usually in a single dose daily.
During therapy with calcitriol, dosage depends on the nature and severity of the patient's hypocalcemia and must be individualized to maintain serum calcium concentrations of 9-10 mg/dL. The manufacturers recommend that serum calcium concentrations be measured at least twice weekly during initial dosage adjustments and after subsequent dosage changes; however, some clinicians recommend that serum calcium concentrations be measured at least weekly for the first 12 weeks of therapy and monthly after stabilization of dosage.
For the management of hypocalcemia and resultant metabolic bone disease in patients with chronic renal failure undergoing dialysis, the usual initial adult oral dosage of calcitriol is 0.25 mcg daily. Some patients with normal or slightly reduced serum calcium concentrations require only 0.25 mcg every other day. If adequate clinical and biochemical responses are not obtained with the initial dosage, the dosage may be increased by 0.25 mcg daily at 4- to 8-week intervals. If hypercalcemia occurs during titration of dosage, calcitriol should be withheld until normocalcemia ensues; the drug can then be reinstituted at a dosage less than that which induced hypercalcemia. Most patients undergoing hemodialysis require oral calcitriol dosages of 0.5-1 mcg daily.
In children undergoing hemodialysis, oral calcitriol dosages of 0.25-2 mcg daily have been used to increase serum calcium and decrease parathyroid hormone concentrations.
For the management of hypocalcemia in patients with chronic renal failure undergoing hemodialysis, the usual initial adult IV dosage of calcitriol is 0.5 mcg (0.01 mcg/kg) 3 times weekly, approximately every other day. The drug may be administered IV by rapid injection through the catheter at the end of a period of hemodialysis. If adequate clinical and biochemical responses are not obtained with the initial dosage, the dose given 3 times weekly may be increased by 0.25-0.5 mcg at 2- to 4-week intervals. If hypercalcemia occurs during titration of dosage, calcitriol should be withheld until normocalcemia ensues; the drug can then be reinstituted at a dosage less than that which induced hypercalcemia. Most patients require IV calcitriol dosages of 0.5-3 mcg (0.01-0.05 mcg/kg) 3 times weekly.
For the management of secondary hyperparathyroidism and resultant metabolic bone disease in adults and pediatric patients 3 years of age and older with moderate to severe renal failure (creatinine clearance of 15-55 mL/minute, corrected for surface area in children) not yet on dialysis, the usual initial oral dosage of calcitriol is 0.25 mcg once daily. If necessary, the dosage may be increased to 0.5 mcg once daily. For predialysis pediatric patients younger than 3 years of age, the usual initial oral dosage of calcitriol is 0.01-0.015 mcg/kg once daily.
Hypoparathyroidism and Pseudohypoparathyroidism
For the management of hypoparathyroidism and pseudohypoparathyroidism in adults and children 1 year of age and older, the usual initial oral dosage of calcitriol is 0.25 mcg daily. If adequate clinical and biochemical responses are not obtained with the initial dosage, the dosage may be increased at 2- to 4-week intervals. If hypercalcemia occurs during titration of dosage, calcitriol should be withheld until normocalcemia ensues; the drug can then be reinstituted at a dosage less than that which induced hypercalcemia. Lowering the patient's dietary calcium intake should also be considered. Most adults and children 6 years of age and older require oral calcitriol dosages of 0.5-2 mcg daily. Most children 1-5 years of age with hypoparathyroidism require oral calcitriol dosages of 0.25-0.75 mcg daily; because of the limited number of children younger than 6 years of age who have received calcitriol for the management of pseudohypoparathyroidism, specific dosage recommendations for these children do not currently exist. A pediatric oral dosage of 0.04-0.08 mcg/kg daily has also been used.
In children and a few adults with vitamin D-dependent rickets, an oral calcitriol dosage of 1 mcg daily has been used to control serum calcium and treat rickets or osteomalacia. In 2 adults with unusual resistance to calcitriol therapy, 12-17 mcg daily was needed to maintain normocalcemia.
In a few patients with familial hypophosphatemia (vitamin D-resistant rickets), 2.1 mcg of oral calcitriol daily increased serum calcium concentrations. Oral phosphate salts may be administered concomitantly.
To manage hypocalcemia in premature infants, 1 mcg of oral calcitriol daily has been used during the first 5 days of life. To control hypocalcemic tetany in premature infants, some clinicians have used an IV calcitriol dosage of 0.05 mcg/kg daily for 5-12 days.